Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Hemoglobin subunit gamma-1 (HBG1) promoter genomic DNA sequence is a critical regulatory region located on chromosome 11 that controls the transcription of the A-gamma globin gene, a key component of fetal hemoglobin (HbF, alpha2gamma2). During fetal development, the HBG1 promoter is active, but it is epigenetically silenced shortly after birth by transcriptional repressors such as BCL11A and ZBTB7A, facilitating the transition to adult hemoglobin (HbA, alpha2beta2). In patients with beta-hemoglobinopathies like sickle cell disease (SCD) and beta-thalassemia, adult hemoglobin is either mutated or deficient, leading to severe clinical complications. Reactivating the expression of fetal hemoglobin by targeting the HBG1 promoter has emerged as a highly promising therapeutic strategy, as elevated HbF levels can functionally compensate for defective adult hemoglobin and prevent red blood cell sickling.\n\nTherapeutic approaches targeting the HBG1 promoter utilize advanced gene-editing technologies, including CRISPR-Cas9, CRISPR-Cas12a, and base editors, to introduce precise modifications. These edits typically disrupt the binding sites of transcriptional repressors (such as BCL11A) or recreate naturally occurring mutations associated with hereditary persistence of fetal hemoglobin (HPFH), a benign condition that maintains high HbF levels into adulthood. Investigational therapies like ristoglogene autogetemcel (BEAM-101) and EDIT-301 target this promoter ex vivo in patient-derived hematopoietic stem and progenitor cells (HSPCs), which are subsequently reinfused to establish a durable, long-term source of healthy, HbF-producing red blood cells.
Disruption of the BCL11A transcriptional repressor binding site or recapitulation of hereditary persistence of fetal hemoglobin (HPFH) mutations via gene editing (CRISPR-Cas9, CRISPR-Cas12a, or base editing) to reactivate fetal hemoglobin (HbF) expression.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hemoglobin subunit gamma-1 promoter genomic DNA sequence (HBG1 promoter).